Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004

<p>Abstract</p> <p>Background</p> <p>Using non-steroidal anti-inflammatory drugs (NSAIDs) as a case, we used Taiwan's National Health Insurance (NHI) database, to empirically explore the association between policy interventions (price regulation, new drug entry, and an information shock) and drug expenditures, utilization, and market structure between 2001 and 2004.</p> <p>Methods</p> <p>All NSAIDs prescribed in ambulatory visits in the NHI system during our study period were included and aggregated quarterly. Segmented regression analysis for interrupted time series was used to examine the associations between two price regulations, two new drug entries (cyclooxygennase-2 inhibitors) and the rofecoxib safety signal and expenditures and utilization of all NSAIDs. Herfindahl index (HHI) was applied to further examine the association between these interventions and market structure of NSAIDs.</p> <p>Results</p> <p>New entry was the only variable that was significantly correlated with changes of expenditures (positive change, p = 0.02) and market structure of the NSAIDs market in the NHI system. The correlation between price regulation (first price regulation, p = 0.62; second price regulation, p = 0.26) and information shock (p = 0.31) and drug expenditure were not statistically significant. There was no significant change in the prescribing volume of NSAIDs per rheumatoid arthritis (RA) or osteoarthritis (OA) ambulatory visit during the observational period. The market share of NSAIDs had also been largely substituted by these new drugs up to 50%, in a three-year period and resulted in a more concentrated market structure (HHI 0.17).</p> <p>Conclusions</p> <p>Our empirical study found that new drug entry was the main driving force behind escalating drug spending, especially by altering the market share.</p

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

<p>Abstract</p> <p>Background</p> <p>Diffusion of new drugs in the health care market affects patients' access to new treatment options and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs), diffused in the health care market in Taiwan.</p> <p>Methods</p> <p>Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan's National Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration (maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were estimated for analyses on the diffusion parameters.</p> <p>Results</p> <p>Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital's prior anti-diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50).</p> <p>Conclusions</p> <p>Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription volume of Anti-diabetic drugs.</p

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

<p>Abstract</p> <p>Background</p> <p>Diffusion of new drugs in the health care market affects patients' access to new treatment options and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs), diffused in the health care market in Taiwan.</p> <p>Methods</p> <p>Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan's National Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration (maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were estimated for analyses on the diffusion parameters.</p> <p>Results</p> <p>Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital's prior anti-diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50).</p> <p>Conclusions</p> <p>Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription volume of Anti-diabetic drugs.</p

Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events

BackgroundDeferasirox (DFX) is an effective and well-tolerated oral iron chelator elevating the adherence to iron chelating therapy among patients with iron overload. However, the US Food and Drug Administration issued a warning about the potential adverse events associated with DFX in 2010. ;MethodsTo examine the risks of gastrointestinal (GI) bleeding, acute liver necrosis, and acute renal failure among DFX users compared with desferrioxamine (DFO) users in a real-world setting, first-time users of DFX or DFO between 2005 and 2008 in Taiwan's National Health Insurance database were observed in this population-based retrospective cohort study. The risks of different adverse events were individually analyzed by Cox proportional hazards models and adjusted by age, sex, concomitant medications, and prior medical conditions. ;ResultsDeferasirox users had the highest incidence rates of GI bleeding (2.03 per 10000 patient-days), acute liver necrosis (0.26 per 10000 patient-days) and acute renal failure (1.45 per 10000 patient-days) compared with other iron chelator users. Compared with DFO users, DFX users were not associated with the risk of GI bleeding (adjusted HR 1.03, 95% CI 0.61-1.74, p=0.90) and the risk of acute liver necrosis (adjusted HR 2.13, 95% CI 0.49-9.33, p=0.32). The association between DFX use and acute renal failure was found to be statistically significant (HR 2.18, 95% CI 1.18-4.02, p=0.01; adjusted HR 2.41, 95% CI 1.27-4.58, p=0.01). ;ConclusionIn this study, we found statistically significant higher risk of acute renal failure and non-statistically significant higher risk of GI bleeding and acute liver necrosis associated with DFX use. More researches are warranted to evaluate the association between DFX use and potential adverse events. Copyright (c) 2014 John Wiley & Sons, Ltd

Changes of the prescription of hormone therapy in menopausal women: An observational study in Taiwan

Abstract Background To evaluate the impact of the 2002 Women's Health Initiative (WHI) study results on the prescription of menopausal hormone therapy (MHT) to treat menopause-related symptoms in Taiwan. Methods This retrospective study participant data collected from women interviewed in 2001 Taiwan's National Health Interview Survey (NHIS) and the National Health Insurance (NHI) outpatient claims for women being treated for menopause-related symptoms. We compared prescriptions made for MHI to women seeking outpatient treatment for menopause-related symptoms before and after the publication of the 2002 WHI to study its effect of prescription behavior in Taiwan. There was one dichotomous outcome variable, which was whether MHT was prescribed or not in an outpatient visit to treat menopause-related symptoms. Results Our study included 504 women 45 years old or above whose outpatient visits for menopause-related symptoms were covered by National Health Insurance in 2002. In total, these 504 women made 2549 outpatient visits to be treated for these symptoms. The proportion of outpatient visits in which MHT was prescribed dropped from 83.0% (n = 1,155) before WHI to 73.0% (n = 844) after WHI. We found a decrease in likelihood that women would be prescribed MHT for menopause-related symptoms after the release of the WHI report (OR = 0.36, 95%CI = 0.25 to 0.52, p Conclusion The WHI report caused a substantial decline in the use of MHT to treat menopause-related symptoms in Taiwan. It was found to exert most of its influence in patients with higher educations, physicians with specialties other than gynecologists and obstetricians, and academic medical centers.</p

A Nationwide Cohort Study of Actinic Keratosis in Taiwan

SummaryBackgroundIncidence of actinic keratosis (AKs) and nonmelanoma skin cancer appears to be increasing worldwide due to increasing levels of ultraviolet radiation, lifestyle changes, and an aging population. However, there is no population-based study focusing on AKs among Asian population. We aimed to investigate the incidence, the treatment pattern, the medical utilization and the risk of malignant neoplasm of the AKs patients in Taiwan.MethodsWe conducted a retrospective cohort study to investigate patients with AKs from 2003 to 2011 by using the National Health Insurance Research Database (NHIRD). The inclusion criteria were patients who had at least two outpatient visits or one hospital admission of AK identified by dermatologist from 2004 to 2011. There were 35,933 patients with AKs (elderly [aged ≥65 years]: n = 17,004; non-elderly [aged <65 years]:18,929 patients).ResultsWe found the incidence rate for AKs among elderly patients was higher than non-elderly. We further found that there were 923 patients were identified skin malignant neoplasm after diagnosis of AKs, and the incidence rate among elderly patients was higher than non-elderly (122.66 vs. 13.80 per 10,000 patient-year).ConclusionsThe AKs incidence rate was low in general population but particular high in elderly population in Taiwan. Our findings warrants further investigation into the relationship between actinic keratosis and the nonmelanoma skin cancer (NMSC) in Asians and may affect the approach toward primary prevention of NMSC in Asians with AKs

The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan

AbstractObjectivesTo evaluate the effect of influenza vaccination on the reduction of the risk of outpatient visits for upper respiratory infection (URI) among the elderly in Taiwan.MethodsThe data for this observational study, consisting of 1729 people aged 65 years or older, were drawn from Taiwan's 2001 National Health Interview Survey. This survey data was then linked with National Health Insurance claim data for December 2001 to November 2002. Survival analysis of Cox proportional hazards model was performed to examine the risk of URI outpatient visits in elderly people vaccinated with the influenza vaccine and those not vaccinated during a year-long study period since the influenza season began. To adjust for potential self-selection bias, we used propensity score method to categorize individuals into two groups, based on the predicted probability of being vaccinated from a logistic regression of spatial random effect. Propensity score group 1 (PSG 1) were those with a predicted probability of being vaccinated lower than 0.5, and PSG 2 were those with a predicted probability of being vaccinated of 0.5 or higher.ResultsThe overall vaccination rate was 50%. Logistic regression showed the probability of being vaccinated was related to the number of outpatient visits for URI before the influenza season began (odds ratio (OR) 1.07; 95% confidence interval (CI) 1.04–1.10). Our first survival analysis showed that being vaccinated significantly reduced the risk of URI outpatient visits in PSG 2 during the 1-year study period (hazard ratio 0.89; 95% CI 0.81–0.97). Separate survival analysis showed that being vaccinated reduced the risk of URI outpatient visits for both PSG groups during the first 3 months of the study period.ConclusionBeing vaccinated could reduce the risk of outpatient visits for URI among the elderly during the influenza season